ライフサイエンスコーパス: pleconaril

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 bitor previously under clinical development (pleconaril).

2 This density could be displaced by pleconaril.

3 , ribavirin, and the anti-picornaviral agent pleconaril.

4 Subjects received either pleconaril 200 mg twice daily (initial dose of 400 mg) o

5 al structures of EV-D68 and its complex with pleconaril, a capsid-binding compound that had been deve

6 nd study assessed the efficacy and safety of pleconaril, a novel antiviral drug with broad-spectrum a

7 studies showing that the antiviral effect of pleconaril against HRV16 is greater on the infectivity o

8 Pleconaril and AG7088 have shown the most promise and ar

9 h small-molecule antiviral compounds such as pleconaril bind and inhibit functions associated with th

10 irus 16 (HRV16) and HRV14 are incubated with pleconaril, drug occupancy in the binding pocket is lowe

11 Other potentially useful treatments, such as pleconaril for enteroviral meningoencephalitis are under

12 hese data support the safety and efficacy of pleconaril in decreasing the signs and symptoms and vira

13 ation adjacent to the likely binding site of pleconaril in these isolates.

14 elates strongly with virus susceptibility to pleconaril inhibition.

15 e development of capsid-function inhibitors (pleconaril), inhibitors of 3C protease (AG7088), and rec

16 We also showed that pleconaril inhibits EV-D68 at a half-maximal effective c

17 Pleconaril is a broad-spectrum antirhinovirus and antien

18 ncy in the binding pocket is lower than when pleconaril is introduced during assembly prior to crysta

19 s after receiving the initial dose of either pleconaril or placebo, subjects were inoculated intranas

20 he virus developed reduced susceptibility to pleconaril, precluding the in-vivo use of this drug.

21 Ten independently derived pleconaril-resistant variants of coxsackievirus B3 were

22 The study results indicate that pleconaril-resistant virus variants are attenuated and s

23 HRV16 than in HRV14 and is more marked with pleconaril than with other compounds.

24 spiratory illness symptom scores (P=.013) in pleconaril-treated as compared with placebo-treated subj

25 Pleconaril (VP 63843) is a novel orally bioavailable sma

26 om patients enrolled in clinical trials with pleconaril were distinct from those that confer natural

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。